This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pitot, H. C. Articles by Ames, M. M. Search for Related Content PubMed PubMed Citation Articles by Pitot, H. C. Articles by Ames, M. M.

Phase I Trial of Dolastatin-10 (NSC 376128) in Patients with Advanced Solid Tumors¹

Divisions of Medical Oncology [H. C. P., E. A. M., C. E., J. R., R. M. G., A. A. A.] and Oncology Research [J. M. R., P. G. B., D. L. W., M. M. A.], Department of Neurology [A. J. W.],and Section of Biostatistics [J. A. S.], Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905

Dolastatin-10 (dola-10) is a potent antimitotic peptide, isolated from the marine mollusk Dolabela auricularia, that inhibits tubulin polymerization. Preclinical studies of dola-10 have demonstrated activity against a variety of murine and human tumors in cell cultures and mice models. The purpose of this Phase I clinical trial was to characterize the maximum tolerated dose, pharmacokinetics, and biological effects of dola-10 in patients with advanced solid tumors. Escalating doses of dola-10 were administered as an i.v. bolus every 21 days, using a modified Fibonacci dose escalation schema. Pharmacokinetic studies were performed with the first treatment cycle. Neurological testing was performed on each patient prior to treatment with dola-10, at 6 weeks and at study termination. Thirty eligible patients received a total of 94 cycles (median, 2 cycles; maximum, 14 cycles) of dola-10 at doses ranging from 65 to 455 µg/m². Dose-limiting toxicity of granulocytopenia was seen at 455 µg/m² for minimally pretreated patients (two or fewer prior chemotherapy regimens) and 325 µg/m² for heavily pretreated patients (more than two prior chemotherapy regimens). Nonhematological toxicity was generally mild. Local irritation at the drug injection site was mild and not dose dependent. Nine patients developed new or increased symptoms of mild peripheral sensory neuropathy that was not dose limiting. This toxicity was more frequent in patients with preexisting peripheral neuropathies. Pharmacokinetic studies demonstrated a rapid drug distribution with a prolonged plasma elimination phase (t_1/2z = 320 min). The area under the concentration-time curve increased in proportion to administered dose, whereas the clearance remained constant over the doses studied. Correlation analysis demonstrated a strong relationship between dola-10 area under the concentration-time curve values and decrease from baseline for leukocyte counts. In conclusion, dola-10 administered every 3 weeks as a peripheral i.v. bolus is well tolerated with dose-limiting toxicity of granulocytopenia. The maximum tolerated dose (and recommended Phase II starting dose) is 400 µg/m² for patients with minimal prior treatment (two or fewer prior chemotherapy regimens) and 325 µg/m² for patients who are heavily pretreated (more than two prior chemotherapy regimens).

This article has been cited by other articles:

				T. L. Simmons, E. Andrianasolo, K. McPhail, P. Flatt, and W. H. Gerwick Marine natural products as anticancer drugs Mol. Cancer Ther., February 1, 2005; 4(2): 333 - 342. [Abstract] [Full Text] [PDF]

				M. P. Goetz, C. Erlichman, A. J. Windebank, J. M. Reid, J. A. Sloan, P. Atherton, A. A. Adjei, J. Rubin, H. Pitot, E. Galanis, et al. Phase I and Pharmacokinetic Study of Two Different Schedules of Oxaliplatin, Irinotecan, Fluorouracil, and Leucovorin in Patients With Solid Tumors J. Clin. Oncol., October 15, 2003; 21(20): 3761 - 3769. [Abstract] [Full Text] [PDF]

				H. C. Pitot, J. M. Reid, J. A. Sloan, M. M. Ames, A. A. Adjei, J. Rubin, P. G. Bagniewski, P. Atherton, D. Rayson, R. M. Goldberg, et al. A Phase I Study of Bizelesin (NSC 615291) in Patients with Advanced Solid Tumors Clin. Cancer Res., March 1, 2002; 8(3): 712 - 717. [Abstract] [Full Text] [PDF]

				C. van Kesteren, E. Cvitkovic, A. Taamma, L. López-Lázaro, J. M. Jimeno, C. Guzman, R. A. A. Mathôt, J. H. M. Schellens, J.-L. Misset, E. Brain, et al. Pharmacokinetics and Pharmacodynamics of the Novel Marine-derived Anticancer Agent Ecteinascidin 743 in a Phase I Dose-finding Study Clin. Cancer Res., December 1, 2000; 6(12): 4725 - 4732. [Abstract] [Full Text]

				U. Vaishampayan, M. Glode, W. Du, A. Kraft, G. Hudes, J. Wright, and M. Hussain Phase II Study of Dolastatin-10 in Patients with Hormone-refractory Metastatic Prostate Adenocarcinoma Clin. Cancer Res., November 1, 2000; 6(11): 4205 - 4208. [Abstract] [Full Text] [PDF]

				T. Madden, H. T. Tran, D. Beck, R. Huie, R. A. Newman, L. Pusztai, J. J. Wright, and J. L. Abbruzzese Novel Marine-derived Anticancer Agents: A Phase I Clinical, Pharmacological, and Pharmacodynamic Study of Dolastatin 10 (NSC 376128) in Patients with Advanced Solid Tumors Clin. Cancer Res., April 1, 2000; 6(4): 1293 - 1301. [Abstract] [Full Text]